5-Fluorouracil toxicity is a significant concern in cancer treatment, as it can lead to severe adverse effects like myelosuppression, gastrointestinal toxicity, and neurotoxicity. Genetic variations, particularly in the dihydropyrimidine dehydrogenase (DPD) enzyme, can increase susceptibility to these toxic effects, necessitating careful monitoring and dose adjustments.